APRE 8-K: ACESOT-1051 clinical update on WEE1 inhibitor APR-1051

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Aprea Therapeutics (APRE) reported an other event, stating it issued a press release with a clinical update from the ACESOT-1051 trial that shows early signals of activity for its WEE1 kinase inhibitor, APR-1051.

The press release is attached as Exhibit 99.1 and incorporated by reference. This notice informs the market of new clinical observations; detailed results and context are contained in the attached press release.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 10/24/2025 - 08:35 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

October 24, 2025

Date of Report (Date of earliest event reported)

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-39069	84-2246769
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


3805 Old Easton Road Doylestown, PA (Address of principal executive offices)	18902 (Zip Code)

Registrant’s telephone number, including area code: (215) 948-4119

(Former name or former address, if changed since last report): Not applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	APRE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01Other Events.

On October 24, 2025, Aprea Therapeutics, Inc. issued a press release providing a clinical update from the ACESOT-1051 trial showing early signals of activity for WEE1 Kinase Inhibitor APR-1051. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description
99.1		Press release dated October 24, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Aprea Therapeutics, Inc.

Dated: October 24, 2025	By:	/s/ Oren Gilad
	Name:	Oren Gilad, Ph.D.
	Title:	President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Aprea Therapeutics (APRE) announce in its 8-K?

The company announced a press release providing a clinical update from the ACESOT-1051 trial showing early signals of activity for WEE1 inhibitor APR-1051.

Which trial is referenced in Aprea Therapeutics’ 8-K?

The ACESOT-1051 trial.

Which investigational therapy is mentioned for APRE?

APR-1051, a WEE1 kinase inhibitor.

Where can I find the detailed clinical update for APRE?

In the press release attached as Exhibit 99.1 and incorporated by reference.

What is Aprea Therapeutics’ trading symbol and exchange?

APRE on The Nasdaq Stock Market LLC.

What exhibit numbers are included?

Exhibit 99.1 (press release) and 104 (Cover Page Interactive Data File).